ARTICLE | Clinical News
Lumiliximab regulatory update
February 12, 2007 8:00 AM UTC
FDA granted Orphan Drug and Fast Track designations for lumiliximab to treat relapsed or refractory chronic lymphocytic leukemia (CLL). Lumiliximab is a monoclonal antibody against CD23. ...